Yi Zhou

Yi Zhou

Auto-generated profile, based on publicly available information

Yi Zhou

Department of Plastic and Aesthetic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, P.R. China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
YZYi Zhou
Yi Zhou
CCChenglong Chen
Chenglong Chen
QQQian Qu
Qian Qu
CZChunhua Zhang
Chunhua Zhang
JWJin Wang
Jin Wang
ZHZhiqi Hu
Zhiqi Hu

14 April 2023 in Science Advances
Verified
Journal Article
Open access
YZYi Zhou
Yi Zhou
LYLunan Yang
Lunan Yang
ZLZhen Liu
Zhen Liu
YSYang Sun
Yang Sun
JHJunfei Huang
Junfei Huang
ZHZhiqi Hu
Zhiqi Hu
Switchable and minimally invasive tissue adhesives have great potential for medical applications. However, on-demand adherence to and detachment from tissue surfaces remain difficult. We fabricated a switchable hydrogel film adhesive by designing pattern-tunable wrinkles to control adhesion. When adhered to a substrate, the compressive stress generated from the bilayer system leads to self-similar wrinkling patterns at short and long wavelengths, regulating the interfacial adhesion. To verify the concept and explore its application, we established a random skin flap model, which is a crucial strategy for repairing severe or large-scale wounds. Our hydrogel adhesive provides sufficient adhesion for tissue sealing and promotes neovascularization at the first stage, and then gradually detaches from the tissue while a dynamic wrinkling pattern transition happens. The gel film can be progressively ejected out from the side margins after host-guest integration. Our findings provide insights into tunable bioadhesion by manipulating the wrinkling pattern transition.

22 March 2021 in Journal of Cosmetic Dermatology
Verified
Journal Article
Closed access
PDF file
QQQian Qu
Qian Qu
YZYi Zhou
Yi Zhou
PSPanli Shi
Panli Shi
LDLijuan Du
Lijuan Du
ZFZhexiang Fan
Zhexiang Fan
YMYong Miao
Yong Miao

13 October 2020 in Oncogene
Verified
Journal Article
Closed access
PDF file
YJYu Jin
Yu Jin
YZYi Zhou
Yi Zhou
WDWenfeng Deng
Wenfeng Deng
YWYuchen Wang
Yuchen Wang
RLRichard J. Lee
Richard J. Lee
YMYun Miao
Yun Miao

1 October 2021 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Closed access
XXXiaojv Xiong
Xiaojv Xiong
QHQin He
Qin He
JLJinhua Liu
Jinhua Liu
RDRui Dai
Rui Dai
HZHui Zhang
Hui Zhang
JLJijun Liu
Jijun Liu
Doxorubicin (DOX) is a chemotherapeutic drug for treating various cancers. However, the DOX-induced cardiotoxicity greatly limits its clinical application. MicroRNAs (miRNAs) are emerged as critical mediators of cardiomyocyte injury. This work explored the function of miR-215-5p in the regulation of DOX-induced mouse HL-1 cardiomyocyte injury. An in vitro model of DOX-treated cardiotoxicity was established in HL-1 cells. Gene expression was measured by RT-qPCR. Cell viability was detected using CCK-8. Cell death and apoptosis were tested using TUNEL, flow cytometry, and caspase 3/7 activity assays. Luciferase reporter assay was used to examine the target of miR-215-5p. We found that DOX induced cardiomyocyte injury and upregulated miR-215-5p in HL-1 cells. Inhibition of miR-215-5p attenuated DOX-induced cardiomyocyte death and apoptosis in vitro. Mechanistical experiments indicated that ZEB2 was targeted by miR-215-5p. Additionally, ZEB2 expression was reduced in DOX-treated HL-1 cells. Rescue assays indicated that ZEB2 knockdown reversed the effects of miR-215-5p inhibition. In conclusion, miR-215-5p inhibition protects HL-1 cells against DOX-induced injury by upregulating ZEB2 expression.

20 March 2017 in Journal of Microscopy
Verified
Journal Article
Closed access
PDF file
CLC.X. Liao
C.X. Liao
ZWZ.Y. Wang
Z.Y. Wang
YZY. Zhou
Y. Zhou
LZL.Q. Zhou
L.Q. Zhou
XZXiaoqin Zhu
Xiaoqin Zhu
JCJ.X. Chen
J.X. Chen